Physician profile
David A Wheeler
NPI 1235184318
$48,669.14
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $13K · 2022: $24.19 · 2023: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $903 · Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $903.27 |
| Food and Beverage | $373.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $26,337.09 | 2019-2020 | |
| Gilead Sciences, INC. | $10,844.06 | 2019-2020 | |
| Viiv Healthcare Company | $9,599.69 | 2019-2022 | |
| Astrazeneca Uk Limited | $1,276.92 | 2023 | |
| Janssen Biotech, INC. | $192.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $117.90 | 2019 | |
| Mylan Institutional INC. | $43.47 | 2019 | |
| Allergan, INC. | $42.91 | 2019-2020 | |
| Insmed, INC. | $36.56 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $30.06 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $23.95 | 2019 | |
| Melinta Therapeutics, LLC | $23.76 | 2019 | |
| Nabriva Therapeutics, Plc | $21.68 | 2020 | |
| Napo Pharmaceuticals INC | $21.49 | 2020 | |
| Astellas Pharma US INC | $15.34 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $14.54 | 2019 | |
| Abbvie INC. | $13.47 | 2019 | |
| Qiagen, LLC | $13.43 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$127,884.56 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.